Neurocrine Biosciences, Inc (NASDAQ: NBIX) is 10.77% higher on its value in year-to-date trading and has touched a low of $110.95 and a high of $157.98 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The NBIX stock was last observed hovering at around $152.42 in the last trading session, with the day’s loss setting it -1.22%.
Currently trading at $151.20, the stock is 3.39% and 10.03% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.43 million and changing -0.80% at the moment leaves the stock 13.02% off its SMA200. NBIX registered 6.67% gain for a year compared to 6-month loss of 2.37%. The firm has a 50-day simple moving average (SMA 50) of $136.865 and a 200-day simple moving average (SMA200) of $133.6874.
The stock witnessed a 9.49% gain in the last 1 month and extending the period to 3 months gives it a 23.72%, and is 0.35% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 2.11% over the week and 2.44% over the month.
Neurocrine Biosciences, Inc (NBIX) has around 1400 employees, a market worth around $15.31B and $2.24B in sales. Current P/E ratio is 40.51 and Fwd P/E is 23.99. Profit margin for the company is 17.21%. Distance from 52-week low is 36.28% and -4.29% from its 52-week high. The company has generated returns on investments over the last 12 months (12.99%).
with sales reaching $629.44M over the same period.The EPS is expected to grow by 58.81% this year, but quarterly earnings will post 24.86% year-over-year. Quarterly sales are estimated to grow 22.17% in year-over-year returns.
886.0 institutions hold shares in Neurocrine Biosciences, Inc (NBIX), with institutional investors hold 95.95% of the company’s shares. The shares outstanding are 101.20M, and float is at 98.54M with Short Float at 3.25%. Institutions hold 95.00% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 14.19 million shares valued at $1.95 billion. The investor’s holdings represent 14.2191 of the NBIX Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 10.06 million shares valued at $1.38 billion to account for 10.0766 of the shares outstanding. The other top investors are STATE STREET CORP which holds 4.61 million shares representing 4.6176 and valued at over $634.43 million, while RENAISSANCE TECHNOLOGIES LLC holds 2.4731 of the shares totaling 2.47 million with a market value of $339.79 million.
Neurocrine Biosciences, Inc (NBIX) Insider Activity
The most recent transaction is an insider sale by Cooke Julie, the company’s Chief Human Resources Officer. SEC filings show that Cooke Julie sold 1,740 shares of the company’s common stock on Jan 31 ’25 at a price of $152.89 per share for a total of $0.27 million. Following the sale, the insider now owns 18202.0 shares.
Neurocrine Biosciences, Inc disclosed in a document filed with the SEC on Jan 31 ’25 that GORMAN KEVIN CHARLES (Director) sold a total of 2,707 shares of the company’s common stock. The trade occurred on Jan 31 ’25 and was made at $152.92 per share for $0.41 million. Following the transaction, the insider now directly holds 0.52 million shares of the NBIX stock.
Still, SEC filings show that on Jan 31 ’25, ROBERTS EIRY (Chief Medical Officer) disposed off 1,457 shares at an average price of $152.80 for $0.22 million. The insider now directly holds 32,373 shares of Neurocrine Biosciences, Inc (NBIX).
